FDA approves AbbVie’s hepatitis treatment By: MarketWatch December 19, 2014 at 15:33 PM EST AbbVie’s new multidrug regimen for hepatitis C was approved by the Food and Drug Administration. Read More >> Related Stocks: AbbVie Enanta Pharmaceutica Gilead Sciences Johnson & Johnson